Bacteriophage Market projected to expand at a CAGR of over 4% throughout the forecast period of 2021-2030

Award winning market research company Fact.MR has published the global bacteriophage market research report. According to the study, the market exhibits high growth potential, expected to yield credible gains through 2021. Long-term prospects also appear positive, with a predicted CAGR exceeding 4% through 2031.

The market was valued at approximately US$ 39 million in 2019, with surging applications in gastroenterology underpinning growth. A study conducted by the University of Gothenburg has established that nearly 40% of adults suffer from at least one functional gastrointestinal disorder, with disorders such as inflammatory bowel diseases being highly prevalent. Excessive reliance on antibiotics has led to a surge in antimicrobial resistance, causing numerous GI problems.

Request a report sample with 170 pages to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5558

According to the World Health Organization, the rate of resistance such as ciprofloxacin ranges between 8.4% and 92.9% for E. coli, and from 4.1% to 79.4% for K. Pneumoniae. Hence, the medical fraternity is investigating alternative treatment approaches, leading to heightened prospects for bacteriophage based supplements. Manufacturers are augmenting their research capacities, increasing the frequency of clinical trials and funding studies by establishing international level coalitions.

“Growing emphasis on maintaining gut microbiome health is prompting increased consumption of bacteriophage infused supplements and medicines. Recent government legislations such as the emergency investigational new drug (eIND) pathway by the US FDA have enabled healthcare settings to incorporate bacteriophage products in their diagnostics and treatment procedures,” remarks a Fact.MR analyst.

Key Takeaways from Fact.MR’s Bacteriophage Market Study

• By product, phage probiotics to enjoy an elevated market share, capturing over 9 out of 10 sales in 2021
• Gastroenterology to remain key bacteriophage therapeutics application area, owing to surging digestive tract disorders
• Oral bacteriophage products administration to remain highly preferred through 2021
• By distribution channel, retail and hospital pharmacies to emerge as the primary bacteriophage selling points
• US to experience high growth in bacteriophage sales, amid recent FDA approvals for the oral ingestion of bacteriophage cocktails in dietary supplements
• Increasing frequency of inhaled phage therapy to heighten growth prospects across the UK
• India, Russia & Georgia to emerge as lucrative bacteriophage markets amid accelerating research and development for determining efficacy of such products

Bacteriophage Market- Prominent Drivers

• The global bacteriophage market is driven by unceasing research & development activities for discovering novel treatment approaches
• Growing burden of antibiotic resistance is prompting patients to opt for safer alternatives, accelerating growth prospects
• Increasing global level coalitions amongst prominent manufacturers to accelerate bacteriophage development to stimulate further growth

Bacteriophage Market- Key Restraints

• Non-approval for human consumption by regulatory authorities due to perceived lacunae in effectiveness to restrain growth
• Uncertainties regarding potential mutations of bacteria strains leading to phage resistance development to limit commercial availability

Get More Insights- https://www.accesswire.com/630981/Bacteriophage-Probiotics-to-generate-over-9-out-10-Sales-Attributed-to-Surging-Antibiotic-Resistance-FactMR

Competitive Landscape

Life Extension, Arthur Andrew Medical, Deerland Probiotics & Enzymes Inc., BioChimPharm, Micreos Human Health, Designs for Health, Accelerated Health Systems Inc., The Biostation, Probiotic America and Microgen are some prominent bacteriophage manufacturers included in Fact.MR’s report. Development of novel phase therapies to cater to specific healthcare requirements.

Life Extension, for instance, manufactures the FLORASSIST^® GI probiotic formula for ensuring the best digestive probiotic benefits. Being gluten free, non-GMO and vegetarian, the formula targets unwanted bacteria with a novel bacteriophage blend with various healthy probiotic strains.

Looking for Specific Region & Segment Analysis? Request Report Customization https://www.factmr.com/connectus/sample?flag=RC&rep_id=5558

In 2019, BioChimPharm received a grant from the Georgian Innovation and Technology Agency for its PowerPhage veterinary antimicrobial. The product is highly effective in fighting harmful bacteria such as Salmonella, E. coli and Shigella, eliminating them without harming the beneficial microflora of the organism.

Key Questions Answered in the Report

• How is the bacteriophage market expected to assume shape in 2021?
• Why is Russia expected to emerge as a lucrative bacteriophage market?
• What drivers are expected to underpin future market outlook?
• Which restraints are expected to hamper the bacteriophages market growth?
• How are regulatory frameworks expected to influence market growth?
• Which are the prominent bacteriophage market players?

Request More Information about Report Methodology

https://www.factmr.com/connectus/sample?flag=RM&rep_id=5558

Strategic Partnerships and Funding by Manufacturers for Development of Phage Therapeutics

Pharmaceutical companies are collaborating with a collective goal to foster innovation by working with biotech firms and companies, governments, and market stakeholders, to enable supportable investments into a novel pipeline of bacteriophage therapy.

For instance, Janssen Pharmaceuticals, Inc. and Locus Biosciences Inc., in 2019, signed a complete license and collaboration agreement to manufacture, develop, and commercialize CRISPR-Cas3-enhanced bacteriophage (crPhage) products for the treatment of various infections, such as respiratory tract infection caused by two key pathogens, and other related infections. For this, Locus will receive US$ 20 million as an initial payment, which is expected to reach US$ 798 million from future sales of the product.

Such partnerships between pharmaceutical companies are aimed at strengthening and accelerating phage therapy development to introduce new therapies by end of this decade.

Explore Fact.MR’s Coverage on the Healthcare Domain

Medical Ceramics Market: A recent study by Fact.MR on the medical ceramics market offers a 10-year forecast from 2021 to 2031. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.

Indirect Calorimeter Market: A detailed assessment of the indirect calorimeter value chain analysis, business execution, and supply chain analysis across regional markets has been covered in Fact.MR’s extensive coverage on the subject. The study incorporates a detailed assessment of the market drivers, opportunities and trends influencing future expansion trajectory over key geographies and segments for the upcoming decade.

Viral Antigens Market: Fact.MR’s incisive coverage on the global viral antigens market provides a holistic view of the prominent expansion dynamics expected to shape future growth prospects. The report covers a detailed analysis of the prominent trends prevailing across key geographies and prominent segments for the next decade.